
Outlook Therapeutics (Nasdaq: $OTLK): The Full LYTENAVA Timeline, The FDA Dispute, And The Real State Of The Story
Outlook Therapeutics is not a simple “approval or no approval” biotech story anymore. It is a long regulatory case study around ophthalmic bevacizumab, multiple FDA Complete Response Letters, an approved European/UK product, repeated financing pressure, management resets, and a retail shareholder base trying to understand whether the U.S. file is still alive or structurally blocked.
Evergreen thesis